

**Gefitinib for the first-line treatment of locally advanced or metastatic non small cell lung cancer**

<http://guidance.nice.org.uk/TA/Wave10/21>

Dear Consultees and Commentators,

At the end of the Appraisal Committee discussion on 4 March 2010 on the STA of gefitinib for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), the ERG noted that they had identified a potential error in the economic model. The Committee agreed to request the Institute to investigate, with the company and the ERG, the impact of the potential error on the economic evaluation.

Because it was not foreseeable at that stage how long it would take to receive responses to the clarification from the manufacturer and the ERG, we were not able to inform you of the next steps in this appraisal any earlier.

We have now received sufficient information to allow a continuation of the Appraisal Committee' deliberations on this topic, and in order to avoid any further delay, we this topic will be discussed at the next Appraisal Committee meeting, 6 April. It will be added to the end of the agenda.

If you have any questions, please contact me.

Best wishes,

Jeremy

**Jeremy Powell**

Technology Appraisal Project Manager

National Institute for Health and Clinical Excellence

MidCity Place | 71 High Holborn | London WC1V 6NA | United Kingdom

Tel: 44 (0)20 7045 2248 | Fax: 44 (0)20 7061 9830